Breaking News

Zymeworks, ProBioGen in Antibody Development Pact

To use GlymaxX Technology to enhance antibody-dependent cell-mediated cytotoxicity

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG and Zymeworks Inc. have entered an agreement under which ProBioGen will complete cell line development of a Zymeworks bi-specific antibody product candidate, applying its GlymaxX Technology to enhance antibody-dependent cell-mediated cytotoxicity (ADCC).   ProBioGen’s chief scientific officer, Dr. Volker Sandig, said, “We have been working productively with Zymeworks for some time already and look forward to contributing to the success of Zymeworks’ Azymetric™ bi-specific antibody...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters